Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Noven's Stavzor Final Approval Anticipated In Mid-2008 After FDA Offers “Tentative Approval”

This article was originally published in The Pink Sheet Daily

Executive Summary

Valproic acid delayed release capsules gain tentative clearance for manic episodes associated with bipolar disorder and multiple seizures, including epilepsy.

You may also be interested in...



Riding On Humira Sales, Abbott Aims For Dominance In Lipid Management Market

Product launches and Humira label expansions will compensate for Depakote generics entering the market in July, CEO White says.

Riding On Humira Sales, Abbott Aims For Dominance In Lipid Management Market

Product launches and Humira label expansions will compensate for Depakote generics entering the market in July, CEO White says.

Noven/Banner Receive FDA “Approvable” Letter For Stavzor

Data requested by the agency to complete the 505(b)(2) NDA is all “non-clinical,” Noven says.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS065564

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel